Neoadjuvant immune checkpoints can guide targeted therapy for GBM; for instance, Siglec-9, an immune checkpoint molecule on macrophages, can directly activate CD4 T and CD8 T cells to affect the treatment of GBM [71]. The gene discussed is CD8A; the disease is glioblastoma.